Shin Nippon Biomedical Laboratories Balance Sheet Health
Financial Health criteria checks 3/6
Shin Nippon Biomedical Laboratories has a total shareholder equity of ¥36.5B and total debt of ¥35.0B, which brings its debt-to-equity ratio to 95.9%. Its total assets and total liabilities are ¥89.0B and ¥52.5B respectively. Shin Nippon Biomedical Laboratories's EBIT is ¥1.9B making its interest coverage ratio 59.1. It has cash and short-term investments of ¥11.2B.
Key information
95.9%
Debt to equity ratio
JP¥34.96b
Debt
| Interest coverage ratio | 59.1x |
| Cash | JP¥11.21b |
| Equity | JP¥36.45b |
| Total liabilities | JP¥52.53b |
| Total assets | JP¥88.98b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YB3's short term assets (¥34.0B) exceed its short term liabilities (¥28.8B).
Long Term Liabilities: YB3's short term assets (¥34.0B) exceed its long term liabilities (¥23.7B).
Debt to Equity History and Analysis
Debt Level: YB3's net debt to equity ratio (65.2%) is considered high.
Reducing Debt: YB3's debt to equity ratio has increased from 67% to 95.9% over the past 5 years.
Debt Coverage: YB3's debt is not well covered by operating cash flow (4.7%).
Interest Coverage: YB3's interest payments on its debt are well covered by EBIT (59.1x coverage).